Immunotherapy and chemo before surgery for triple-negative breast cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug combination given before surgery for triple-negative breast cancer. The drugs include an immunotherapy medication (AK112) and standard chemotherapy, and the goal is to see if it helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75.
- You have been diagnosed with triple-negative breast cancer that has not spread to other parts of the body (stage T1-4N0-3M0, but not T1N0M0).
- You have a tumor that can be measured and plan to have surgery to remove it.
- You have not received any prior chemotherapy, radiation, immunotherapy, or other cancer treatment for this disease.
- You do not have an active autoimmune disease or other cancer in the past 5 years (except treated skin or cervical cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
This trial tests a new combination of drugs given before surgery for triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This trial tests a combination of stereotactic body radiation therapy (SBRT), chemotherapy, and an immunotherapy drug called AK104 given before surgery to treat triple-negative breast cancer. It aims to see if this approach can shrink tumors more effectively and help patients avoid a mastectomy.
This study tests giving a combination of chemotherapy and immunotherapy before surgery for early stage triple negative breast cancer. The goal is to see if this approach can improve treatment outcomes and reduce the chance of the cancer coming back.
Hear when a new Breast Cancer Female trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.